Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open Label, Dose Escalation Study to Determine Safety and Immunogenicity of Two (Prophylactic) COVID 19 DNA Vaccine Candidates (VB10.2129 [C1], a RBD Candidate and VB10.2210 [C2], a T Cell Candidate), in Healthy Adult Volunteers

NCT05069623 is registered in ClinicalTrials.gov with Nykode Therapeutics ASA as lead sponsor.

NCT NCT05069623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05069623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open Label, Dose Escalation Study to Determine Safety and Immunogenicity of Two (Prophylactic) COVID 19 DNA Vaccine Candidates (VB10.2129 [C1], a RBD Candidate and VB10.2210 [C2], a T Cell Candidate), in Healthy Adult Volunteers
Lead sponsor
Nykode Therapeutics ASA
Phase
Phase 1/2
Overall status
Completed
Start date
November 1, 2021
Completion date
May 30, 2023
Enrollment
68 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, infection viral, infections